{"groups":[{"description":"Patients received 1000 mg /m\\^2 of gemcitabine on Day 1 and 8 and 175 mg/m\\^2 of paclitaxel on Day 1 intravenously every 21 days for 6 cycles ( 1 cycle = 21 days)","id":"FG000","title":"Paclitaxel + Gemcitabine (Elderly Cohort: Age >= 70)"},{"description":"Patients received 1000 mg /m\\^2 of gemcitabine on Day 1 and 8 and 175 mg/m\\^2 of paclitaxel on Day 1 intravenously every 21 days for 6 cycles ( 1 cycle = 21 days)","id":"FG001","title":"Paclitaxel + Gemcitabine (Younger Cohort: Age < 60)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"11"},{"groupId":"FG001","numSubjects":"1"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}],"type":"Refusal unrelated to adverse event"},{"reasons":[{"groupId":"FG000","numSubjects":"9"},{"groupId":"FG001","numSubjects":"2"}],"type":"Progression/relapse"},{"reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"0"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"2"}],"type":"Other - not protocol specified"},{"reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"0"}],"type":"Ineligible"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"55"},{"groupId":"FG001","numSubjects":"10"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"51"},{"groupId":"FG001","numSubjects":"10"}],"type":"Eligible"},{"achievements":[{"groupId":"FG000","numSubjects":"23"},{"groupId":"FG001","numSubjects":"5"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"32"},{"groupId":"FG001","numSubjects":"5"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"The purpose of the subset of patients who aged 60 years or younger was to serve as a younger reference group for the pharmacokinetic parameter estimation. Therefore, this younger cohort is not included in analyses of adverse event, efficacy, and feasibility assessment of patient-reported outcome measures."}